Ionis Pharmaceuticals, Inc. (IONS) /
The cash flow of Ionis Pharmaceuticals, Inc. over the past 10 years
Chart Ionis Pharmaceuticals, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Ionis Pharmaceuticals, Inc.'s operating cash flow was -$268.58M and its capital expenditures $51.44M, leaving free cash flow of -$320.03M. Free cash flow was above zero in 5 of the 10 years shown. It ranged from -$546.23M in fiscal 2024 to $585.25M in fiscal 2018. Capital expenditures were highest in fiscal 2025, at $51.44M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$268.58M | $51.44M | -$320.03M |
| 2024ended Dec 31, 2024 | -$500.95M | $45.28M | -$546.23M |
| 2023ended Dec 31, 2023 | -$307.51M | $23.8M | -$331.32M |
| 2022ended Dec 31, 2022 | -$274.37M | $15.72M | -$290.09M |
| 2021ended Dec 31, 2021 | $30.8M | $11.96M | $18.84M |
| 2020ended Dec 31, 2020 | $35.89M | $35.12M | $772K |
| 2019ended Dec 31, 2019 | $345.63M | $30.91M | $314.72M |
| 2018ended Dec 31, 2018 | $602.91M | $17.65M* | $585.25M |
| 2017ended Dec 31, 2017 | $174.15M | $34.76M | $139.38M |
| 2016ended Dec 31, 2016 | -$112.11M | $7.11M | -$119.21M |
Fiscal years as Ionis Pharmaceuticals, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Ionis Pharmaceuticals, Inc.
- The revenue of Ionis Pharmaceuticals, Inc.
- The profitability of Ionis Pharmaceuticals, Inc.
- The debt of Ionis Pharmaceuticals, Inc.
- All of Ionis Pharmaceuticals, Inc.'s financials, charted
Companies of a similar size
- EPAMEPAM SYSTEMS, INC.
- CVLTCommvault Systems, Inc
- CAGCONAGRA BRANDS, INC.
- MSAMSA SAFETY INC
- KEXKIRBY CORPORATION
Not investment advice. This page shows what Ionis Pharmaceuticals, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.